Feeds:
Posts
Comments

Posts Tagged ‘Dendreon Corp (DNDN.O)’

XCONOMY SEATTLE: Dendreon’s immune-stimulating therapy for prostate cancer, called Provenge, was able to improve median survival time by 4.1 months, and lowered the risk of death by 22.5 percent, according to long-awaited clinical trial results presented at the American Urological Association annual meeting today. READ MORE> and HERE>

Read Full Post »

REUTERS:  OFFICIAL  approval is a step closer in the US for the first cancer immunotherapy –  a drug to fight cancer by stimulating the immune system to attack cancer cells – after the latest trials on more than 500 men with late-stage prostate cancer. READ MORE>

Read Full Post »